Compare SHFS & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SHFS | ENVB |
|---|---|---|
| Founded | 2015 | 1994 |
| Country | United States | United States |
| Employees | 41 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7M | 3.0M |
| IPO Year | N/A | 2000 |
| Metric | SHFS | ENVB |
|---|---|---|
| Price | $0.83 | $5.19 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 270.6K | ★ 8.0M |
| Earning Date | 04-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $39,914,675.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.71 | $0.56 |
| 52 Week High | $9.18 | $13.25 |
| Indicator | SHFS | ENVB |
|---|---|---|
| Relative Strength Index (RSI) | 47.53 | 79.70 |
| Support Level | $0.78 | $4.15 |
| Resistance Level | $1.01 | $6.54 |
| Average True Range (ATR) | 0.13 | 0.93 |
| MACD | 0.00 | 0.33 |
| Stochastic Oscillator | 27.37 | 56.40 |
SHF Holdings Inc is a financial services provider to cannabis-related businesses. It offers reliable access to banking solutions for cannabis, hemp, CBD, and ancillary operators, making communities safer, driving growth in local economies, and fostering long-term partnerships. The group, through its financial institution clients, implements accountability, transparency, monitoring, reporting, and risk mitigation measures while meeting Bank Secrecy Act obligations in line with FinCEN guidance on cannabis-related businesses. Its services include Program Management Support, Customer Generation, Ongoing Program Auditing, and Compliance Monitoring, among others.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.